Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All budesonide studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBudesonideBudesonide (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19

Baker et al., medRxiv, doi:10.1101/2021.10.26.21265512
Oct 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Budesonide for COVID-19
20th treatment shown to reduce risk in April 2021
 
*, now known with p = 0.000025 from 14 studies, recognized in 8 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Analysis of inflammatory mediators in the nasal mucosa of patients in the STOIC1 trial and a cohort of SARS-CoV-2 negative controls, showing that budesonide treatment decreased IL-33 and IFN-γ, implying a reduction in epithelial damage and dampening of the interferon response. Treatment also increased CCL17 concentrations, suggesting improved T-cell response.
Baker et al., 27 Oct 2021, preprint, 10 authors.
This PaperBudesonideAll
Dampening of the respiratory cytokine storm is promoted by inhaled budesonide in patients with early COVID-19
Jonathan R Baker, Mahdi Mahdi, Dan V Nicolau Jr, Sanjay Ramakrishnan, Peter J Barnes, Jodie L Simpson, Steven P Cass, Richard Ek Russell, Louise E Donnelly, Professor Mona Bafadhel
doi:10.1101/2021.10.26.21265512
Vaccinations against SARS-CoV-2 are effective in COVID-19. However, with limited vaccine access, vaccine hesitancy and variant breakthroughs, there is still a need for effective and safe early treatments. Two community-based clinical trials of the inhaled corticosteroid, budesonide, have recently been published showing and improvement in patients with COVID-19 treated early with budesonide 1,2 . To understand mechanistically how budesonide was beneficial, inflammatory mediators were assessed in the nasal mucosa of patients recruited to the Steroids in COVID (STOIC 1 ) trial and a cohort of SARS-CoV-2 negative individuals. Here we show that in early COVID-19, elevation in viral response proteins and Th1 and Th2 inflammation occurs. Longitudinal sampling in the natural course of COVID-19 showed persistently high interferon levels and elevated concentrations of the eosinophil chemokine, CCL11. In patients who deteriorate, the initial nasal mucosal signal is characterised by a marked suppression of the early inflammatory response, with reduced concentrations of interferon and inflammatory cytokines, but elevated eosinophil chemokines. Systemic inflammation remained altered in COVID-19 patients, implying that even after symptom resolution, changes in immunological mediators do not resolve. Budesonide treatment decreased IL-33 and IFN-γ, implying a reduction in epithelial damage and dampening of the interferon response. Budesonide treatment also increased CCL17 concentrations, suggesting an improved T-cell response; and significantly alters inflammatory pathways giving further insight into how this treatment can accelerate patient recovery. . This finding has now been replicated in a large Phase 3 efficacy trial 2 , but has yet to attract global adoption. The mechanism for how ICS can improve early COVID-19 infection is however currently unknown. Here, we report the nasal mucosal inflammatory response in patients with early COVID-19 disease and examine the evolution of inflammation in the natural course of COVID-19. We also identify how inflammation in the airway can predict illness severity and investigate the effect of inhaled budesonide upon the respiratory mucosa in early COVID-19 disease. Finally, we show using network analysis how inhaled budesonide can resolve the exaggerated inflammatory response seen in early COVID-19 infection and promote resolution to health.
Methods Study design and participants STOIC was a randomised, open-label, parallel group, phase 2 clinical intervention trial. Participants aged 18 and over with early COVID-19 symptoms (defined as new onset of cough and/or fever and/or anosmia for less than 7 days) were randomised to receive usual care (UC), namely as required anti-pyretics, or inhaled budesonide (BUD) at a dose of 800μg twice a day plus usual care (see supplement figure S1 ). Participants were seen at home at randomisation day 0 (visit 1), day 7 (visit 2), and day 14 (visit 3) by a research nurse to obtain consent, provide inhalers and collect nasal absorption samples and nasopharyngeal swabs which were self-performed. At day 28 (visit 4), whole Nasal mucosal sampling Nasal mucosal sampling was self-performed by all participants as previously described 37 . Briefly, samples of the nasal mucosal lining fluid were collected by placing a Nasosorption™ FX•I device (Hunt Developments UK Ltd) consisting of a synthetic absorptive matrix strip against the inferior turbinate for a duration of 1 minute. The sample was then eluted in 500 μL of PBS, 1% bovine serum albumin (BSA) (w/v), 1% Triton X-100 (v/v), and 0.05% sodium azide (w/v) (Sigma-Aldrich, UK) and stored at -80°C. Isolation of serum
References
Bafadhel, Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers, Am J Respir Crit Care Med, doi:10.1164/rccm.201104-0597OC
Bafadhel, Pavord, Russell, Eosinophils in COPD: just another biomarker?, Lancet Respir Med, doi:10.1016/S2213-2600(17)30217-5
Barnes, Inhaled Corticosteroids, Pharmaceuticals, doi:10.3390/ph3030514
Blondel, Guillaume, Lambiotte, Lefebvre, Fast unfolding of communities in large networks, Journal of Statistical Mechanics: Theory and Experiment, doi:10.1088/1742-5468/2008/10/p10008
Bloom, Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK, Lancet Respir Med, doi:10.1016/S2213-2600(21)00013-8
Chua, COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis, Nature Biotechnology, doi:10.1038/s41587-020-0602-4
Farr, Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection, PLoS Pathog, doi:10.1371/journal.ppat.1009759
Finney, Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon, The Journal of allergy and clinical immunology, doi:10.1016/j.jaci.2020.09.034
Gleich, Mechanisms of eosinophil-associated inflammation, J Allergy Clin Immunol, doi:10.1067/mai.2000.105712
Guan, Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis, Eur Respir J, doi:10.1183/13993003.00547-2020
Guo-Parke, Linden, Weldon, Kidney, Taggart, Mechanisms of Virus-Induced Airway Immunity Dysfunction in the Pathogenesis of COPD Disease, Progression, and Exacerbation, Frontiers in Immunology, doi:10.3389/fimmu.2020.01205
Hadjadj, Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients, Science, doi:10.1126/science.abc6027
Han, Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors, Emerging Microbes & Infections, doi:10.1080/22221751.2020.1770129
Hoffmann, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Iyengar, Jain, Vaishya, Ish, Long COVID-19: an emerging pandemic in itself, Adv Respir Med, doi:10.5603/ARM.a2021.0040
Lee, Ashkar, The Dual Nature of Type I and Type II Interferons, Frontiers in Immunology, doi:10.3389/fimmu.2018.02061
Leist, Schäfer, Martinez, Cell and animal models of SARS-CoV-2 pathogenesis and immunity, Disease Models & Mechanisms, doi:10.1242/dmm.046581
Liao, Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19, Nature Medicine, doi:10.1038/s41591-020-0901-9
Lucas, Longitudinal analyses reveal immunological misfiring in severe COVID-19, Nature, doi:10.1038/s41586-020-2588-y
Marchenko, Pastur, Распределение собственных значений в некоторых ансамблях случайных матриц
Mason, Thoughts on the alveolar phase of COVID-19, American Journal of Physiology-Lung Cellular and Molecular Physiology, doi:10.1152/ajplung.00126.2020
Message, Johnston, The immunology of virus infection in asthma, European Respiratory Journal, doi:10.1183/09031936.01.00228701
Milne, Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial, Eur Respir J, doi:10.1183/13993003.00130-2021
Morton, Distinct clinical and immunological profiles of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa, Nature communications, doi:10.1038/s41467-021-23267-w
Murira, Lamarre, Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection, Frontiers in Immunology, doi:10.3389/fimmu.2016.00609
Papi, Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations, Am J Respir Crit Care Med, doi:10.1164/rccm.200506-859OC
Peluso, Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms, Cell Rep, doi:10.1016/j.celrep.2021.109518
Ramakrishnan, Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial, Lancet Respir Med, doi:10.1016/s2213-2600(21)00160-0
Rogliani, Lauro, Di Daniele, Chetta, Calzetta, Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?, Expert Rev Respir Med, doi:10.1080/17476348.2021.1850275
Rouse, Sehrawat, Immunity and immunopathology to viruses: what decides the outcome?, Nature Reviews Immunology, doi:10.1038/nri2802
Saris, Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID-19, Thorax, doi:10.1136/thoraxjnl-2020-216256
Scheller, Chalaris, Garbers, Rose-John, ADAM17: a molecular switch to control inflammation and tissue regeneration, Trends in Immunology, doi:10.1016/j.it.2011.05.005
Sudre, Attributes and predictors of long COVID, Nature Medicine, doi:10.1038/s41591-021-01292-y
Tan, Viruses in asthma exacerbations, Curr Opin Pulm Med, doi:10.1097/01.mcp.0000146781.11092.0d
Thwaites, Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19, Sci Immunol, doi:10.1126/sciimmunol.abg9873
Valle, An inflammatory cytokine signature predicts COVID-19 severity and survival, Nature medicine, doi:10.1038/s41591-020-1051-9
Vareille, Kieninger, Edwards, Regamey, The airway epithelium: soldier in the fight against respiratory viruses, Clin Microbiol Rev, doi:10.1128/CMR.00014-10
Yamaya, Nishimura, Nadine, Kubo, Nagatomi, Formoterol and budesonide inhibit rhinovirus infection and cytokine production in primary cultures of human tracheal epithelial cells, Respir Investig, doi:10.1016/j.resinv.2014.03.004
Yu, Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial, Lancet, doi:10.1016/S0140-6736(21)01744-X
Zhou, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit